Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension

References

• Tunnel vision : The Economic Impact of Primary Open Angle Glaucoma-A Dynamic Economic ModelCentre for Eye Research Australia2008
   Google Scholar
• MitchellPSmithWAtteboKPrevalence of open-angle glaucoma in Australia. The Blue Mountains Eye StudyOphthalmology199610310166198874440
   PubMed Web of Science ®Google Scholar
• KleinBEKleinRSpinselWEPrevalence of glaucoma. The Beaver Dam Eye StudyOphthalmology19929914995041454314
   PubMed Web of Science ®Google Scholar
• The AGIS investigatorsThe Advanced Glaucoma Intervention Study (AGIS):7. The relationship between control of intraocular pressure and visual field deteriorationAm J Ophthalol200013042940
   PubMed Web of Science ®Google Scholar
• Neuroprotection and Glaucoma; Current Concepts2002OxfordInstitiute
   Google Scholar
• TorisCBCamrasCBYablonskiMEAcute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patientsAm J Ophthalmol1999128181410482088
   PubMed Web of Science ®Google Scholar
• CantorLBThe evolving pharmacotherapeutic profile of brimonidine, an alpha2-adrenergic agonist, after four years of continuous useExpert Opin Pharmacother200018153411249518
   PubMedGoogle Scholar
• WaltersTRDevelopment and use of brimonidine in treating acute and chronic elevations of intraocular pressure, a review of safety, efficacy, dose response and dosing studiesSurv Ophthalmol199641S19S268970246
   PubMed Web of Science ®Google Scholar
• WeinrebRNLevinLAIs neuroprotection a viable therapy for glaucoma?Arch Ophthalmol19991171540410565524
   PubMed Web of Science ®Google Scholar
• WheelerLAGilDWWoldeMussieERole of alph2adrenergic receptors in neuroprotection and glaucomaSurv Ophthalmol200145Suppl 3S29029411377451
   PubMed Web of Science ®Google Scholar
• BylundDBChackoDMCharacterization of alpha2 adrenergic receptor subtypes in human ocular tissue. IvestOphthalmol Vis Sci1999402299306
   PubMed Web of Science ®Google Scholar
• BurkeJManlapazCKharlambATherapeutic use of a2-adrenoreceptor agonists in glaucomaLanierSMLimbirdLEAlpha-Adrenergic Receptors Structure, Function and Therapeutic ImplicationsReading, UKHarwood Academic Publishers199617987
   Google Scholar
• KentANussdorfJDavidRVitreous concentrations of topically applied brimonidine tartrate 0.2%Ophthalmology2001108784711297498
   PubMed Web of Science ®Google Scholar
• WoldeMussieERuizGWijonoMWheelerLANeuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertensionInvest Ophthalmol Vis Sci20014228495511687528
   PubMed Web of Science ®Google Scholar
• HernandezMUrcolaJHVecinoERetinal ganglion cell neuroprortection in a rat model of glaucoma following brimonidine, latanoprost or combined treatmentsExp Eye Res20088679880618394603
   PubMed Web of Science ®Google Scholar
• WheelerLALaiRWolenMussieEFrom the lab to the clinic: activation of an alpha-2 agonist pathway is neuroprtoective in models of retinal and optic nerve injuryEur J Ophthalmol19999Suppl 1S172110230601
   PubMed Web of Science ®Google Scholar
• DonelloJEPadilloEUWebsterMLAlpha(2)-adrenoceptoragonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischaemiaJ Pharmacol Exp Ther20012962162311123383
   PubMed Web of Science ®Google Scholar
• WheelerLATattonNAElstnerMAlpha-2 adrenergic receptor activation by brimondine reduces neuronal apoptosis through Akt (ptrotien Kinase B) dependent new synthesis of BCL-2Invest Opthalmol Vis Sci200142S411
   Web of Science ®Google Scholar
• AungTOenFTWongHTRandomised controlled trial comparing the effect of brimonidine and timolol on visual field loss after acute primary angle closureBr J Ophthalmol2004881889414693782
   PubMed Web of Science ®Google Scholar
• FerenczJRGiladyGHarelOTopical brimonidine reduces collateral damage caused by laser photocoagulation for choroidal neovascularizationGraefes Arch Clin Exp Ophthalmol20052438778015785924
   PubMed Web of Science ®Google Scholar
• TsaiJCChangHWComparison of the effects of brimonidine 0.2% and timolo 0.5% on retinal nerve fiber layer thickness in ocular hypertensive patients: a prospective, unmasked studyJ Ocul Pharmacol Ther20051221647482
   Web of Science ®Google Scholar
• GandolfiSASangermaniCCiminoLIs there a non IOP-related effect of brimonidine on visual field progression in human glaucoma?IOVS200445ARVO E-abstract 2298
   Google Scholar
• EvansDWHoskingSLGherghelDBarlettJDContrast sensitivity improves after brimonidine therapy in primary open angle glaucoma: a case for neuroprotectionBr J Ophthalmol200387121463514660453
   PubMed Web of Science ®Google Scholar
• KrupinTLiebmannJMGreenfieldDSRosenbergLFRitchRThe Low-pressure Glaucoma Treatment Study (LoGTS) Study design and baseline characteristics of enrolled patientsOphthalmology20051123768515745762
   PubMed Web of Science ®Google Scholar
• KrupinTSpecial consideration in low tension glaucomaCan J Ophthalmol200742414717508037
   PubMed Web of Science ®Google Scholar
• Market Share Data for Australia, from IMS June 2008
   Google Scholar
• KatzLJFor the Brimonidine Study Groups 1 and 2. Twice-daily brimonidine tartrate 0.2% vs timolol 0.5%: 1 year results in glaucoma patientsAm J Ophthalmol19991272069932994
   PubMed Web of Science ®Google Scholar
• SchumanJSHorwitzBChoplinNTA 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trialArch Ophthalmol1997115847529230823
   PubMed Web of Science ®Google Scholar
• LeBlancRPfor the Brimonidine Study Group 2Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol given twice daily in patients with glaucoma or ocular hypertensionOphthalmology1998105196079787370
   PubMed Web of Science ®Google Scholar
• MelamedSDavidRfor the Brionidine Study group 2Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: three year resultsClin Ther2000221031110688394
   PubMed Web of Science ®Google Scholar
• CantorLBThe evolving pharmacotherapeutic profile of brimonidine, an alpha 2-adrenergic agonist, after for years of continuous useExp Opin Pharmcother20001481534
   PubMedGoogle Scholar
• GoldbergIGoldbergHBetaxlol eye drops. A clinical trial of safety and efficacyAust N Z J Ophthalmol19952317247619450
   PubMedGoogle Scholar
• GoldbergIThe safety of topical beta-blockers in glaucoma treatmentMed J. Aust19961644949
   Web of Science ®Google Scholar
• JavittJGoldbergIFor the Brimonidine Outcomes Study Group 2. Comparison of the clinical success rates and quality of life of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertensionJ Glaucoma2000939840811039742
   PubMed Web of Science ®Google Scholar
• SerleJBA comparison of the safety and efficacy of twice daily brimonidine 0.2% versus Betaxolol 0.25% in subjects with elevated intraocular pressureSurv Ophthalmol1996419 suppl 1S39478970248
   PubMed Web of Science ®Google Scholar
• HodgeWGLachaineJSteffensenIThe efficacy and harm of prostaglandin analogues for the IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic reviewBr J Ophthalmol20089271218156371
   PubMed Web of Science ®Google Scholar
• WhitsonJTHenryCHughesBComparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertensionJ Glaucoma2004131687315097265
   PubMed Web of Science ®Google Scholar
• StewartWCSharpeEDHarbinTSJrBrimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocularpressureAm J Opthalmol2001297237
   Google Scholar
• SharpeEDDayDGBeischelCJBrimonidine purite 0.15% versus dorzolamide 2% each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertensionBr J Ophthalmol200488953615205246
   PubMed Web of Science ®Google Scholar
• SimmonsSTEfficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertensionClin Ther2001236041911354394
   PubMed Web of Science ®Google Scholar
• LeeDAGornbeinJAEffectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open label community trialJ Glaucoma200110220611442187
   PubMed Web of Science ®Google Scholar
• KonstasAGKarabatsasCHLallosN24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjectsOphthalmology2005112603815808251
   PubMed Web of Science ®Google Scholar
• SherwoodMBCravenERChouCTwice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trialArch Ophthlmol200612412308
   PubMed Web of Science ®Google Scholar
• ChoudriSWandMShieldsMBA Comparison of dorzolamide-timolol combination versus the concomitant drugsAm J Opthalmol2001308323
   Web of Science ®Google Scholar
• EverittDEAvornJSystemic effects of medications used to treat glaucomaAnn Int Med199011212051967209
   PubMed Web of Science ®Google Scholar
• CantorLBHoopJKatzLJFor the Alphagan/Betaxolol Clinical Success Study Group. Comparison of the clinical success and quality-of-life impact of brimonidine 0.2% and betaxolol 0.25% suspension in patients with elevated intraocular pressureClin Ther20012371032911519768
   PubMed Web of Science ®Google Scholar
• ThompsonCDMacDonaldTLGarstMEMechanisms of adrenergic agonist induced allergy:bioactivation and antigen formationExp Eye Res1997645767739245907
   PubMed Web of Science ®Google Scholar
• AbelsonMBChapinMBatoosinghAA retrospective examination of drug-induced allergy to Alphagan and a proposal for a new reporting systemInvest Opthalmol Vis Sci1999404S515 Abstract 2718
   Web of Science ®Google Scholar
• ManniGCentofantiMSacchettiMDemographic and clinical factors associated with the development of alphagan induced allergyJ Glaucoma2004132163715097264
   PubMed Web of Science ®Google Scholar
• BerdyGJAbelsonMBSmithIMGeorgeMAPreservative-free artificial tear preparations. Assessment of corneal epithelial toxic effectsArch Ophthalmol1992110528321562263
   PubMed Web of Science ®Google Scholar
• NoeckerREffects of common ophthalmic preservatives on ocular healthAdv Ther2001185
   Web of Science ®Google Scholar
• KatzLJTwelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertensionJ Glaucoma2002111192611912359
   PubMed Web of Science ®Google Scholar
• MundorfTWilliamsRWhitcupSA 3 month comparison of efficacy and safety of brimonidine–purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertensionJ Ocular Pharmacol Ther2003191
   Web of Science ®Google Scholar
• EnyediLBFreedmanSFSafety and efficacy of brimonidine in children with glaucomaJ AAPOS200255281411641636
   PubMed Web of Science ®Google Scholar
• TsaiJCMcClureCARamosSECompliance barriers in glaucoma: A systematic classificationJ Glaucoma200312393814520147
   PubMed Web of Science ®Google Scholar
• NordstromBLFriedmanDSMozaffariEPersistence and adherence with topical glaucoma therapyAm J Ophthalmol200514059860616226511
   PubMed Web of Science ®Google Scholar
• MotolkoMAComparison of allergy rates in glaucoma patients receiving brimonidine 0.2% monotherapy versus fixed-combination brimonidine 0.2%-timolol 0.5% therapyCurr Med Res Opin200886 [Epub ahead of print]
   Web of Science ®Google Scholar
• ChanKTestaMMcCluskeyPOcular Comfort of Combination Glaucoma Therapies:Brimonidine 0.2%/Timolol 0.5% Compared with Dorzolamide2%/Timolol 0.5%J Ocul Pharmacol Ther2007324372617803436
   PubMed Web of Science ®Google Scholar
• OsborneSAMontgomeryDMMorrisDMcKayICAlphagan allergy may increase the propensity for multiple eye-drop allergyEye2005191293715254495
   PubMed Web of Science ®Google Scholar
• AlvaroadoJAReduced ocular allergy with fixed-combination 0.2% brimonidine-0.5% timololArch Ophthalmol200712571717502523
   PubMedGoogle Scholar